Agilent Technologies Inc A:NYSE

Last Price$123.92NYSE Closing Price as of 4:10PM ET 1/26/21
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change-1.56(1.24%)
Bid (Size)$123.80 (1)
Ask (Size)$130.00 (1)
Day Low / High$123.87 - 125.95
Volume1.5 M

View Medical Specialties IndustryPeer Comparison as of 01/26/2021


Agilent Technologies Inc ( NYSE )

Price: $123.92
Change: -1.56 (1.24%)
Volume: 1.5 M
4:10PM ET 1/26/2021

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $161.75
Change: +0.43 (0.27%)
Volume: 2.4 M
4:00PM ET 1/26/2021

Biogen Inc ( NASDAQ )

Price: $271.67
Change: -3.87 (1.40%)
Volume: 777.2 K
3:59PM ET 1/26/2021

Seagen Inc ( NASDAQ )

Price: $172.64
Change: -7.48 (4.15%)
Volume: 1.3 M
3:59PM ET 1/26/2021

Exact Sciences Corp ( NASDAQ )

Price: $141.04
Change: -12.89 (8.37%)
Volume: 2.6 M
4:00PM ET 1/26/2021

Read more news Recent News

Research Alert: CFRA Lifts View On Shares Of Agilent Technologies, Inc. To Buy From Hold
12:25PM ET 1/19/2021 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Agilent Raises Q1 Core Revenue Growth Outlook
6:10AM ET 1/12/2021 MT Newswires

Agilent Technologies (A) said Monday it expects Q1 core revenue growth to be "at least in the high single digits range", stronger than its previous...

Agilent Technologies Secures Japanese Clearance for Use of Postnatal Assay
4:44AM ET 12/23/2020 MT Newswires

Agilent Technologies (A) said Tuesday it has secured clearance from the Japanese Ministry of Health, Labour and Welfare for its GenetiSure Dx Postnatal...

Analyst Actions: SVB Leerink Adjusts Agilent Technologies' Price Target to $130 from $120, Maintains Outperform Rating
9:36AM ET 12/10/2020 MT Newswires

Agilent Technologies (A) has an average rating of outperform and price targets ranging from $77 to $132, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionAgilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. View company web site for more details
Address5301 Stevens Creek Boulevard
Santa Clara, California 95051
Number of Employees14,800
Recent SEC Filing01/21/20214/A
President, Chief Executive Officer & DirectorMichael R. McMullen
Chief Financial Officer & Senior Vice PresidentRobert W. McMahon
Chief Technology Officer & Senior Vice PresidentDarlene J. S. Solomon
Senior Vice PresidentJacob Thaysen

Company Highlights

Price Open$125.50
Previous Close$125.48
52 Week Range$61.13 - 129.34
Market Capitalization$38.0 B
Shares Outstanding306.8 M
SectorHealth Technology
IndustryMedical Specialties
Current Dividend / Yield$0.19 / 0.62%
Dividend Ex-Date01/04/2021
Dividend Pay-Date01/27/2021
Dividend Yield 5 Year Average0.86%
Next Earnings Announcement02/16/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings54.56
Earnings per Share$2.52
Beta vs. S&P 500N/A
Revenue$4.9 B
Net Profit Margin13.47%
Return on Equity14.77%

Analyst Ratings as of 01/14/2021

Consensus RecommendationConsensus Icon
Powered by Factset